Scholarlink

<p>Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies and becomes an increasing burden on our society, with nearly half of patients presenting with metastasis at diagnosis and a mortality rate that continues to rise during the past decade. Despite significant advances in understanding the molecular heterogeneity of PDAC, current classifications have yet to translate into clinical practice. In this review, we propose a novel clinical classification for stage IV PDAC based on distinct patterns of metastatic dissemination and highlight the ongoing efforts to tailor specific regimens for specific clinical subtypes. We further explore the underlying molecular mechanisms that may drive site-specific metastasis. We suggest that the new clinical subtypes could improve patient stratification, optimize clinical trial design, and ultimately enhance therapeutic outcomes in stage IV PDAC patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical subtypes of stage IV pancreatic ductal adenocarcinoma: a new perspective of clinical practices

  • 期刊论文

  • 发表日期：

    2025年10月21日

查看全文
  • Yi-Fei Zhang,
  • Wei Gan,
  • Wen-Quan Wang,
  • Liang Liu

摘要

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies and becomes an increasing burden on our society, with nearly half of patients presenting with metastasis at diagnosis and a mortality rate that continues to rise during the past decade. Despite significant advances in understanding the molecular heterogeneity of PDAC, current classifications have yet to translate into clinical practice. In this review, we propose a novel clinical classification for stage IV PDAC based on distinct patterns of metastatic dissemination and highlight the ongoing efforts to tailor specific regimens for specific clinical subtypes. We further explore the underlying molecular mechanisms that may drive site-specific metastasis. We suggest that the new clinical subtypes could improve patient stratification, optimize clinical trial design, and ultimately enhance therapeutic outcomes in stage IV PDAC patients.